Shares of Geron Co. (NASDAQ:GERN) have received an average rating of “Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $3.33.
A number of equities analysts have issued reports on GERN shares. Zacks Investment Research cut shares of Geron from a “hold” rating to a “sell” rating in a research report on Monday, February 22nd. HC Wainwright reiterated a “buy” rating on shares of Geron in a research report on Thursday. Finally, B. Riley reiterated a “buy” rating on shares of Geron in a research report on Wednesday, February 17th.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James & Associates bought a new stake in Geron during the third quarter worth about $30,000. Hsbc Holdings PLC bought a new stake in Geron during the fourth quarter worth about $43,000. Teacher Retirement System of Texas boosted its stake in Geron by 59.4% during the fourth quarter. Teacher Retirement System of Texas now owns 28,562 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 10,648 shares in the last quarter. Credit Agricole S A boosted its stake in Geron by 50.0% during the fourth quarter. Credit Agricole S A now owns 30,000 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Truist Financial Corp boosted its stake in Geron by 241.1% during the fourth quarter. Truist Financial Corp now owns 34,107 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 24,107 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.
Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, March 10th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Geron had a negative net margin of 21,631.02% and a negative return on equity of 43.76%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.08 million. During the same quarter in the previous year, the firm posted ($0.15) EPS. Sell-side analysts anticipate that Geron will post -0.27 EPS for the current year.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production.
See Also: Trading on Margin
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.